Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates
May 17, 2021 06:30 ET
|
Cerevel Therapeutics
Announced strategic $125 million non-dilutive financing for tavapadon Welcomed Abraham Ceesay as President Appointed Scott Akamine as Chief Legal Officer Phase 1b trial for CVL-231 in...
Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer
May 04, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021
April 29, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics Appoints Abraham N. Ceesay as President
April 21, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the...
Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
April 13, 2021 06:30 ET
|
Cerevel Therapeutics
Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon...
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results
March 24, 2021 06:30 ET
|
Cerevel Therapeutics
Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 IND submitted for CVL-871 in dementia-related apathy Conference call and webcast...
Cerevel Therapeutics to Present at the Stifel 3rd Annual CNS Day Event
March 22, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
February 24, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference
February 23, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs
January 28, 2021 07:00 ET
|
Cerevel Therapeutics
Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid...